<scp>WMJ</scp>‐<scp>S</scp>‐001, a novel aliphatic hydroxamate derivative, exhibits anti‐inflammatory properties via <scp>MKP</scp>‐1 in <scp>LPS</scp>‐stimulated <scp>RAW</scp>264.7 macrophages

Abstract

WMJ-S-001 may activate MKP-1, which then dephosphorylates p38MAPK, resulting in a decrease in p65 and C/EBPβ binding to the COX-2 promoter region and COX-2 down-regulation in LPS-stimulated RAW264.7 macrophages. The present study suggests that WMJ-S-001 may be a potential drug candidate for alleviating LPS-associated inflammatory diseases.